Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
UDPS combined with genotypic algorithms for prediction of HIV-1 co-receptor usage may provide quantitative data about the tropism of each variant present in the viral quasispecies. The aim of the present study was to assess co-receptor usage by ultra-deep pyrosequencing (UDPS), in comparison with the reference phenotypic test (Trofile), in patients who are candidates for CCR5 antagonist treatment, in both circulating and proviral HIV-1. Seventeen patients who were tested by Trofile were enrolled. UDPS of the V3 loop region was carried out on both plasma RNA and proviral DNA. Genotypic prediction of co-receptor usage was established by position-specific score matrices (PSSM) and confirmed, in discordant cases, with geno2pheno. Genetic heterogeneity of the RNA and DNA quasispecies was assessed as well. A total of 196,729 V3 sequences were considered (mean coverage per site, 6346). Concordance between phenotypic test and UDPS with PSSM was 0.82. Geno2pheno results were in line with those obtained with PSSM. Proviral quasispecies were more heterogeneous than those found in circulating HIV. In most patients eligible for CCR5 antagonist treatment, X4 variants were detected in proviral DNA, ranging from 1.0% to 52.7%. UDPS combined with genotypic algorithms for co-receptor usage prediction highlighted the presence of minority variants, with a discordant tropism with respect to the predominant population, in both circulating viral and proviral HIV. In most patients treated with Maraviroc the virological response was independent of the presence of X4 in proviral DNA. The clinical impact of minority X4 variants present in patients who are candidates for anti-CCR5 antagonists remains a crucial point to be addressed.
Abbate
I
I
National Institute for Infectious Diseases INMI L. Spallanzani, Roma, Italy.
Rozera
G
G
Tommasi
C
C
Bruselles
A
A
Bartolini
B
B
Chillemi
G
G
Nicastri
E
E
Narciso
P
P
Ippolito
G
G
Capobianchi
M R
MR
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D016679:Genome, Viral; D006678:HIV / Q000235:genetics* / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D019713:Receptors, CCR5 / Q000235:genetics; D015728:Receptors, HIV / Q000235:genetics*; D017422:Sequence Analysis, DNA; D017423:Sequence Analysis, RNA; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D019713:Receptors, CCR5; D015728:Receptors, HIV; D014230:Triazoles; D000077592:Maraviroc